Screener
Monte Rosa Therapeutics, Inc. GLUE Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized, 85,226,427 and 65,543,723 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 9 | 7 |
| Additional paid-in capital | 1,057,551 | 714,090 |
| Accumulated other comprehensive loss | (5,165) | (3,827) |
| Accumulated deficit | (565,114) | (477,214) |
| Total stockholders’ equity | 487,281 | 233,056 |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s common stock?
- Monte Rosa Therapeutics, Inc. (GLUE) reported common stock of $9K in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s common stock changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s common stock increased by 50.0% year-over-year, from $6K to $9K.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s common stock has grown at a 47.6% compound annual growth rate (CAGR), from $1K to $7K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Monte Rosa Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude